Understanding Your Journey with Abetalipoproteinemia (ABL)
At a Glance
Abetalipoproteinemia is a rare inherited condition in which too little MTTP prevents normal transport of dietary fat and vitamins A, D, E, and K. Early, supervised vitamin therapy, a specialized low-fat diet, and lifelong monitoring can reduce or delay serious nerve and eye complications.
Receiving a diagnosis of abetalipoproteinemia (often shortened to ABL) can feel overwhelming, especially because it is an exceptionally rare condition. It is estimated to affect fewer than one in a million people worldwide [1]. Because it is so uncommon, many patients and families spend years searching for answers, often visiting multiple specialists before the correct diagnosis is made [2]. Understanding how this condition works and what to expect is the first step in taking control of your health journey.
Key Safety Point: Vitamin and dietary treatments for ABL require careful medical supervision. Do not change your doses on your own, as these vitamins can be toxic at excessive levels. Any persistent symptoms warrant clinical review rather than self-adjustment.
Why the Body Struggles with Fat
At its core, abetalipoproteinemia is a genetic condition that changes how your body handles fats and certain vitamins. It is caused by a shortage of a specific protein called microsomal triglyceride transfer protein (MTTP) [3][4].
Normally, the body uses MTTP like a shipping manager in the gut and liver. Its job is to help package fats and fat-soluble vitamins into “transport ships” called lipoproteins [5][6]. Without enough MTTP, your body is severely impaired in building or releasing these transport ships. As a result:
- Fats from your diet stay trapped in your intestinal cells instead of moving efficiently into your bloodstream [3].
- Your blood levels of cholesterol and triglycerides become extremely low [3][7].
- Your body cannot effectively absorb critical fat-soluble vitamins—specifically vitamins A, D, E, and K—which are vital for your eyes, nerves, and bones [3][8].
The Typical Course of the Condition
The way ABL shows up can vary from person to person, but it often follows a predictable path from infancy into adulthood if it is not treated.
Infancy and Childhood
For most, symptoms begin in the first few months of life. Because babies cannot absorb fat, they often experience steatorrhea (pale, oily, foul-smelling stools), vomiting, and poor weight gain or growth faltering—historically called “failure to thrive”—meaning the child is not gaining weight or growing as expected [3][9].
Adulthood and Progression
If the condition is left untreated, the long-term lack of vitamins begins to affect other parts of the body. By the second or third decade of life, complications can become more serious [10]:
- Neurological Impact: You may develop ataxia (problems with balance and coordination), tremors, or muscle weakness [3][11].
- Vision Changes: Severe, chronic vitamin E deficiency (and vitamin A deficiency) can lead to retinal degeneration resembling retinitis pigmentosa, a condition that causes night blindness and a gradual loss of side vision [3][8].
- Blood and Liver: You may see acanthocytosis, where red blood cells take on a “spiky” shape, or develop a “fatty liver” because fat is trapped in the liver cells [3][9].
The Impact of Treatment
While there is currently no cure for ABL, the outlook changes significantly with early and consistent management. The goal of treatment is to bypass the body’s broken “shipping system” for fats and vitamins.
- Treated Outcomes: When high-dose vitamin therapy and a specialized low-fat diet are started early, many of the most severe complications can be stabilized, delayed, lessened, or prevented [12][3]. While outcomes vary substantially, some patients who follow strict treatment plans have lived into their 70s and 80s [3][10]. However, established functional damage to nerves and eyes may not be fully reversible.
- Untreated Outcomes: Historically, without treatment, the cumulative damage to the nerves and eyes can lead to severe progressive disability, including significant vision loss or loss of the ability to walk, by early adulthood [3][8].
Navigating the Emotional Journey
Living with a “one-in-a-million” condition brings unique emotional challenges. It is common to feel isolated or frustrated by the lack of public awareness. Because the condition requires lifelong management—including a very specific diet and high-dose supplements—it can affect everything from family meals to school and work life [13].
You are not alone in this process. Organizations like the Abetalipoproteinemia and Related Disorders Foundation exist specifically to provide guidance and connect families facing these same challenges [13]. Connecting with a multidisciplinary care team—including a metabolic specialist, a nutritionist, a neurologist, and an eye doctor—is essential for monitoring your health and maintaining your quality of life [14][9].
Common questions in this guide
What causes abetalipoproteinemia?
What symptoms can abetalipoproteinemia cause?
How is ABL treated?
Can treatment reverse damage caused by abetalipoproteinemia?
Which specialists should care for someone with ABL?
Get notified when new evidence is published on Abetalipoproteinemia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (14)
- 1
Comorbid Abetalipoproteinemia and Neurofibromatosis Type 1: Potential Clinical Implications of an Ultrarare Co-occurrence.
Womack YHM, Asif MB, Shamoun FE, et al.
Annals of internal medicine. Clinical cases 2026; (5(7)) doi:10.7326/aimcc.2026.0224.
PMID: 42614189 - 2
Ophthalmic diagnosis and optical coherence tomography of abetalipoproteinemia, a treatable form of pediatric retinal dystrophy.
Khan AO, Basamh O, Alkatan HM
Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus 2019; (23(3)):176-177 doi:10.1016/j.jaapos.2019.01.005.
PMID: 30731125 - 3
Current Diagnosis and Management of Abetalipoproteinemia.
Takahashi M, Okazaki H, Ohashi K, et al.
Journal of atherosclerosis and thrombosis 2021; (28(10)):1009-1019 doi:10.5551/jat.RV17056.
PMID: 33994405 - 4
High carrier frequency for abetalipoproteinemia and evidence of a founder variant in a French-Canadian population.
Guay SP, Paquette M, Girard L, et al.
Journal of clinical lipidology 2024; (18(4)):e625-e630 doi:10.1016/j.jacl.2024.04.132.
PMID: 38908974 - 5
Microsomal Triglyceride Transfer Protein: From Lipid Metabolism to Metabolic Diseases.
Iqbal J, Jahangir Z, Al-Qarni AA
Advances in experimental medicine and biology 2020; (1276()):37-52 doi:10.1007/978-981-15-6082-8_4.
PMID: 32705593 - 6
Lipid transfer proteins in the assembly of apoB-containing lipoproteins.
Sirwi A, Hussain MM
Journal of lipid research 2018; (59(7)):1094-1102 doi:10.1194/jlr.R083451.
PMID: 29650752 - 7
Postprandial lipid absorption in seven heterozygous carriers of deleterious variants of MTTP in two abetalipoproteinemic families.
Di Filippo M, Varret M, Boehm V, et al.
Journal of clinical lipidology 2019; (13(1)):201-212 doi:10.1016/j.jacl.2018.10.003.
PMID: 30522860 - 8
Forty year follow-up of three patients with complete absence of apolipoprotein B-containing lipoproteins.
Le R, Zhao L, Hegele RA
Journal of clinical lipidology 2022; (16(2)):155-159 doi:10.1016/j.jacl.2022.02.003.
PMID: 35221233 - 9
A novel p.Gly417Valfs*12 mutation in the MTTP gene causing abetalipoproteinemia: Presentation of the first patient in Mexico and analysis of the previously reported cases.
Rodríguez Gutiérrez PG, González García JR, Castillo De León YA, et al.
Journal of clinical laboratory analysis 2021; (35(3)):e23672 doi:10.1002/jcla.23672.
PMID: 33258201 - 10
Thirty-Three Years Follow-Up of a Greek Family with Abetalipoproteinemia: Absence of Liver Damage on Long-Term Medium Chain Triglycerides Supplementation.
Triantafillidis JK, Manioti A, Pittaras T, et al.
Journal of personalized medicine 2025; (15(8)) doi:10.3390/jpm15080354.
PMID: 40863416 - 11
Deep brain stimulation in Bassen-Kornzweig syndrome: Still effective after 22 years.
Cortier J, Vandamme S, Vanhauwaert D, et al.
Brain & spine 2023; (3()):101762 doi:10.1016/j.bas.2023.101762.
PMID: 38021030 - 12
Abetalipoproteinemia Due to a Novel Splicing Variant in MTTP in 3 Siblings.
Vlasschaert C, McIntyre AD, Thomson LA, et al.
Journal of investigative medicine high impact case reports 2021; (9()):23247096211022484 doi:10.1177/23247096211022484.
PMID: 34078172 - 13
Guidance for the diagnosis and treatment of hypolipidemia disorders.
Bredefeld C, Hussain MM, Averna M, et al.
Journal of clinical lipidology 2022; (16(6)):797-812 doi:10.1016/j.jacl.2022.08.009.
PMID: 36243606 - 14
Lipids Responsible for Intestinal or Hepatic Disorder: When to Suspect a Familial Intestinal Hypocholesterolemia?
Sissaoui S, Cochet M, Poinsot P, et al.
Journal of pediatric gastroenterology and nutrition 2021; (73(1)):4-8 doi:10.1097/MPG.0000000000003145.
PMID: 33853111
This page explains abetalipoproteinemia, its treatment, and long-term outlook for informational purposes only and does not constitute medical advice. Work with your metabolic specialist and nutrition professional before changing vitamin doses or your diet.